Expertise in
16
conditions

Sandrine Joulin-Jousse

CHU De Brest
Brest, FR 
Expertise in
16
conditions
CHU De Brest
Brest, FR 

Overview

Sandrine Joulin-Jousse practices practicing medicine in Brest, France.

Ms. Joulin-Jousse is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Dry Mouth, Sjogren Syndrome, Dry Eye Syndrome, and Synovitis.

She is actively involved in clinical research, co-authoring 131 peer reviewed articles and participating in 7 clinical trials.

Gender

Female

Locations

CHU de Brest
Brest, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

ULnar Nerve ECHographic Observation (ULNECHO)
ULnar Nerve ECHographic Observation (ULNECHO)
Enrollment Status: Completed
Publish Date: December 03, 2025
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: November 17, 2025
Intervention Type: Drug
Study Drug: ABX464
Study Phase: Phase 2
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Completed
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
Study Phase: Phase 3
Pragmatic Study Comparing the Clinical Evlauation Methods ( C) and / or Ultrasound Method ( B or D) in Rheumatoid Arthritis (RA) to Adapt Treatment
Pragmatic Study Comparing the Clinical Evlauation Methods ( C) and / or Ultrasound Method ( B or D) in Rheumatoid Arthritis (RA) to Adapt Treatment
Enrollment Status: Completed
Publish Date: December 12, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Enrollment Status: Completed
Publish Date: February 15, 2023
Intervention Type: Drug
Study Drugs: ABX464, Methotrexate
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 6 Less Clinical Trials

131 Total Publications

Erratum to: How ultrasound changed the practice of rheumatology: echoes of a 30-year collaboration.
Erratum to: How ultrasound changed the practice of rheumatology: echoes of a 30-year collaboration.
Journal: Zeitschrift fur Rheumatologie
Published: June 03, 2026

Frequently Asked Questions about Sandrine Joulin-Jousse

Is Sandrine Joulin-Jousse a top-rated expert for Dry Mouth?

MediFind is an objective health platform that identifies experts based on real-world data. Sandrine Joulin-Jousse is classified as an Elite expert for Dry Mouth, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Sandrine Joulin-Jousse participate in research or clinical trials?

Yes. Sandrine Joulin-Jousse has published 131 articles and abstracts on conditions like Dry Mouth. You can view a list of Sandrine Joulin-Jousse's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Joulin-Jousse's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile